Intravesical Liposome and Antisense Treatment for Detrusor Overactivity and Interstitial Cystitis/painful Bladder Syndrome

Overview

Journal ISRN Pharmacol

Date 2014 Feb 15

PMID 24527221

Citations 5

Authors

Pradeep Tyagi

Mahendra P Kashyap

Naoki Kawamorita

Tsuyoshi Yoshizawa

Michael Chancellor

Naoki Yoshimura

Affiliations

Soon will be listed here.

Abstract

Purpose. The following review focuses on the recent advancements in intravesical drug delivery, which brings added benefit to the therapy of detrusor overactivity and interstitial cystitis/painful bladder syndrome (IC/PBS). Results. Intravesical route is a preferred route of administration for restricting the action of extremely potent drugs like DMSO for patients of interstitial cystitis/painful bladder syndrome (IC/PBS) and botulinum toxin for detrusor overactivity. Patients who are either refractory to oral treatment or need to mitigate the adverse effects encountered with conventional routes of administration also chose this route. Its usefulness in some cases can be limited by vehicle (carrier) toxicity or short duration of action. Efforts have been underway to overcome these limitations by developing liposome platform for intravesical delivery of biotechnological products including antisense oligonucleotides. Conclusions. Adoption of forward-thinking approaches can achieve advancements in drug delivery systems targeted to future improvement in pharmacotherapy of bladder diseases. Latest developments in the field of nanotechnology can bring this mode of therapy from second line of treatment for refractory cases to the forefront of disease management.

Citing Articles

Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome.

Li J, Yi X, Ai J Int J Mol Sci. 2022; 23(23).

PMID: 36498919 PMC: 9736130. DOI: 10.3390/ijms232314594.

Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment.

Jiang Y, Jhang J, Lee Y, Kuo H Biomedicines. 2022; 10(2).

PMID: 35203604 PMC: 8962423. DOI: 10.3390/biomedicines10020396.

Intravesical liposome drug delivery and IC/BPS.

Janicki J, Gruber M, Chancellor M Transl Androl Urol. 2016; 4(5):572-8.

PMID: 26816855 PMC: 4708561. DOI: 10.3978/j.issn.2223-4683.2015.08.03.

Advances in intravesical therapy for urinary tract disorders.

Tyagi P, Kashyap M, Hensley H, Yoshimura N Expert Opin Drug Deliv. 2015; 13(1):71-84.

PMID: 26479968 PMC: 4955766. DOI: 10.1517/17425247.2016.1100166.

Single compartment drug delivery.

Cima M, Lee H, Daniel K, Tanenbaum L, Mantzavinou A, Spencer K J Control Release. 2014; 190:157-71.

PMID: 24798478 PMC: 4179298. DOI: 10.1016/j.jconrel.2014.04.049.

References

Caccin P, Rossetto O, Rigoni M, Johnson E, Schiavo G, Montecucco C . VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett. 2003; 542(1-3):132-6. DOI: 10.1016/s0014-5793(03)00365-x. View

Gebhard C, Huard G, Kritikou E, Tardif J . Apolipoprotein B antisense inhibition--update on mipomersen. Curr Pharm Des. 2013; 19(17):3132-42. DOI: 10.2174/13816128113199990312. View

Tyagi P, Chancellor M, Yoshimura N, Huang L . Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU Int. 2007; 101(5):627-32. DOI: 10.1111/j.1464-410X.2007.07334.x. View

Saban M, Hellmich H, Nguyen N, Winston J, Hammond T, Saban R . Time course of LPS-induced gene expression in a mouse model of genitourinary inflammation. Physiol Genomics. 2001; 5(3):147-60. DOI: 10.1152/physiolgenomics.2001.5.3.147. View

Bade J, Laseur M, Nieuwenburg A, van der Weele L, Mensink H . A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol. 1997; 79(2):168-71. DOI: 10.1046/j.1464-410x.1997.03384.x. View

Johnson J, Nayar R, Killion J, Von Eschenbach A, Fidler I . Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer. Sel Cancer Ther. 1989; 5(4):147-55. DOI: 10.1089/sct.1989.5.147. View

Hanno P . Analysis of long-term Elmiron therapy for interstitial cystitis. Urology. 1997; 49(5A Suppl):93-9. DOI: 10.1016/s0090-4295(97)00179-9. View

Tyagi P, Thomas C, Yoshimura N, Chancellor M . Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol. 2009; 35(1):76-83. DOI: 10.1590/s1677-55382009000100012. View

Yokota T, Hoffman E, Takeda S . Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Methods Mol Biol. 2011; 709:299-312. PMC: 4491489. DOI: 10.1007/978-1-61737-982-6_20. View

10.

Tyagi V, Philips B, Su R, Smaldone M, Erickson V, Chancellor M . Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol. 2009; 181(4):1932-8. DOI: 10.1016/j.juro.2008.11.078. View

11.

Blietz C, Thode B, Hauses M, Pries R, Meyer A, Doehn C . In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer. In Vivo. 2009; 23(1):13-9. View

12.

Chuang Y, Tyagi P, Huang C, Yoshimura N, Wu M, Kaufman J . Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009; 182(2):786-92. DOI: 10.1016/j.juro.2009.03.083. View

13.

Lee W, Chuang Y, Lee W, Chiang P . Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. Kaohsiung J Med Sci. 2011; 27(10):437-40. DOI: 10.1016/j.kjms.2011.06.002. View

14.

Arum C, Kodama Y, Rolim N, WiderOe M, Anderssen E, Viset T . A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma. World J Urol. 2010; 28(4):479-85. DOI: 10.1007/s00345-010-0542-6. View

15.

Vinson S, Rickard A, Ryerse J, McHowat J . Neutrophil adherence to bladder microvascular endothelial cells following platelet-activating factor acetylhydrolase inhibition. J Pharmacol Exp Ther. 2005; 314(3):1241-7. DOI: 10.1124/jpet.105.085365. View

16.

Smith C, Gangitano D, Munoz A, Salas N, Boone T, Aoki K . Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int. 2008; 52(6):1068-75. PMC: 2440726. DOI: 10.1016/j.neuint.2007.11.006. View

17.

Sapra P, Tyagi P, Allen T . Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005; 2(4):369-81. DOI: 10.2174/156720105774370159. View

18.

Yoshimura N, Bennett N, Hayashi Y, Ogawa T, Nishizawa O, Chancellor M . Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci. 2006; 26(42):10847-55. PMC: 6674760. DOI: 10.1523/JNEUROSCI.3023-06.2006. View

19.

Kashyap M, Kawamorita N, Tyagi V, Sugino Y, Chancellor M, Yoshimura N . Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. J Urol. 2013; 190(2):757-64. PMC: 3734554. DOI: 10.1016/j.juro.2013.02.090. View

20.

Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor M . Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005; 65(2):238-42. DOI: 10.1016/j.urology.2004.11.021. View